Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine
Suvi Lappalainen,Ana Ruth Pastor,Maria Malm,Vanessa López-Guerrero,Fernando Esquivel-Guadarrama,Laura A. Palomares,Timo Vesikari,Vesna Blazevic +7 more
TLDR
A non-live combined RV – norovirus (NoV) vaccine candidate consisting of human RV inner-capsid rVP6 protein and NoV virus-like particles is developed, and at least 65 % protection against RV shedding was observed regardless of delivery route.Abstract:
Live oral rotavirus (RV) vaccines are part of routine childhood immunization but are associated with adverse effects, particularly intussusception. We have developed a non-live combined RV – norovirus (NoV) vaccine candidate consisting of human RV inner-capsid rVP6 protein and NoV virus-like particles. To determine the effect of delivery route on induction of VP6-specific protective immunity, BALB/c mice were administered a vaccine containing RV rVP6 intramuscularly, intranasally or a combination of both, and challenged with murine RV. At least 65 % protection against RV shedding was observed regardless of delivery route. The levels of post-challenge serum VP6-specific IgA titers correlated with protection.read more
Citations
More filters
Journal ArticleDOI
Current and new rotavirus vaccines
TL;DR: Rotavirus vaccines have demonstrated impact in reducing diarrheal morbidity and mortality worldwide and could be an essential part of the expansion of rotavirus vaccine use worldwide.
Journal ArticleDOI
The rotavirus vaccine development pipeline
TL;DR: A review of the new rotavirus vaccines in development by developing country manufacturers and rationale why newer candidates continue to be explored can be found in this paper, with the major aim to improve the global supply and for local implementation, and to improve vaccine effectiveness in developing settings.
Journal ArticleDOI
Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors.
TL;DR: The factors that might contribute to the low vaccine efficacy are reviewed, including passive transfer of maternal rotav virus antibodies, rotavirus seasonality, oral polio vaccine (OPV) administered concurrently, microbiome composition and concomitant enteric pathogens, malnutrition, environmental enteropathy, HIV, and histo blood group antigens.
Journal ArticleDOI
Norovirus Vaccine: Priorities for Future Research and Development.
Susanna Esposito,Nicola Principi +1 more
TL;DR: The road to formulation of an effective and safe NoV vaccine seems to be definitively traced, but many problems still need to be solved before the total burden of NoV infections can be adequately controlled.
Journal ArticleDOI
Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries
TL;DR: The role of maternal immunity, received by infants either transplacentally or orally from breast milk, in rotavirus vaccine (RV) performance is evaluated here and higher levels of transplacental rotav virus-specific IgG antibody contribute to reduced vaccine seroconversion.
References
More filters
Journal ArticleDOI
Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine
Timo Vesikari,David O. Matson,Penelope H. Dennehy,Pierre Van Damme,Mathuram Santosham,Zoe M. Rodriguez,Michael J. Dallas,Joseph F. Heyse,Michelle G. Goveia,Steven Black,Henry R. Shinefield,Celia D. C. Christie,Samuli Ylitalo,Robbin F. Itzler,Michele L. Coia,Matthew T. Onorato,Ben A. Adeyi,Gary S. Marshall,Leif Gothefors,Dirk Campens,Aino Karvonen,James P. Watt,Katherine L. O'Brien,Mark J. DiNubile,H Fred Clark,John W. Boslego,Paul A. Offit,Penny M. Heaton +27 more
TL;DR: This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts, and the risk of intussusception was similar in vaccine and placebo recipients.
Journal ArticleDOI
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios,Irene Pérez-Schael,F. Raúl Velázquez,Hector Abate,Thomas Breuer,Sue Ann Costa Clemens,Brigitte Cheuvart,Felix Espinoza,Paul Gillard,Bruce L. Innis,Yolanda Cervantes,Alexandre da Costa Linhares,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Vesta Richardson,Doris Maribel Rivera-Medina,Luis Rivera,Belén Salinas,Noris Pavía-Ruz,Jorge Salmerón,Ricardo Rüttimann,Juan Carlos Tinoco,Pilar Rubio,Ernesto Nuñez,M. Lourdes Guerrero,Juan Pablo Yarzabal,Silvia Damaso,Nadia Tornieporth,Xavier Sáez-Llorens,Rodrigo Vergara,Timo Vesikari,Alain Bouckenooghe,Ralf Clemens,Beatrice De Vos,Miguel O'Ryan +35 more
TL;DR: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.
Journal ArticleDOI
Effect of human rotavirus vaccine on severe diarrhea in African infants.
Shabir A. Madhi,Nigel A. Cunliffe,Duncan Steele,Desiree Witte,Mari Kirsten,Cheryl Louw,Bagrey Ngwira,John C. Victor,Paul Gillard,Brigitte Cheuvart,Htay Htay Han,Kathleen M. Neuzil +11 more
TL;DR: Human rotvirus vaccine significantly reduced the incidence of severe rotavirus gastroenteritis among African infants during the first year of life.
Journal ArticleDOI
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial
George Armah,Samba O. Sow,Robert F. Breiman,Robert F. Breiman,Michael J. Dallas,Milagritos D. Tapia,Daniel R. Feikin,Daniel R. Feikin,Fred Binka,A. Duncan Steele,Kayla F. Laserson,Kayla F. Laserson,Nana Akosua Ansah,Myron M. Levine,Kristen D.C. Lewis,Michele L. Coia,Margaret Attah-Poku,Joel Ojwando,Joel Ojwando,Stephen B. Rivers,John C. Victor,Geoffrey Nyambane,Geoffrey Nyambane,Abraham Hodgson,Florian Schödel,Max Ciarlet,Kathleen M. Neuzil +26 more
TL;DR: In infants in developing countries in Asia, pentavalentrotavirus vaccine is safe and efficacious against severe rotavirus gastroenteritis, and the results support expanded WHO recommendations to promote its global use.
Journal ArticleDOI
The influence of antigen organization on B cell responsiveness
Martin F. Bachmann,Urs Hoffmann Rohrer,Thomas M. Kündig,Kurt Bürki,Hans Hengartner,Rolf M. Zinkernagel +5 more
TL;DR: In VSV-G (IND) transgenic mice, B cells were unresponsive to the poorly organized VSV -G (ind) present as self antigen but responded promptly to the same antigen presented in the highly organized form.
Related Papers (5)
Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.
Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus Vaccine
Timo Vesikari,David O. Matson,Penelope H. Dennehy,Pierre Van Damme,Mathuram Santosham,Zoe M. Rodriguez,Michael J. Dallas,Joseph F. Heyse,Michelle G. Goveia,Steven Black,Henry R. Shinefield,Celia D. C. Christie,Samuli Ylitalo,Robbin F. Itzler,Michele L. Coia,Matthew T. Onorato,Ben A. Adeyi,Gary S. Marshall,Leif Gothefors,Dirk Campens,Aino Karvonen,James P. Watt,Katherine L. O'Brien,Mark J. DiNubile,H Fred Clark,John W. Boslego,Paul A. Offit,Penny M. Heaton +27 more
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios,Irene Pérez-Schael,F. Raúl Velázquez,Hector Abate,Thomas Breuer,Sue Ann Costa Clemens,Brigitte Cheuvart,Felix Espinoza,Paul Gillard,Bruce L. Innis,Yolanda Cervantes,Alexandre da Costa Linhares,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Vesta Richardson,Doris Maribel Rivera-Medina,Luis Rivera,Belén Salinas,Noris Pavía-Ruz,Jorge Salmerón,Ricardo Rüttimann,Juan Carlos Tinoco,Pilar Rubio,Ernesto Nuñez,M. Lourdes Guerrero,Juan Pablo Yarzabal,Silvia Damaso,Nadia Tornieporth,Xavier Sáez-Llorens,Rodrigo Vergara,Timo Vesikari,Alain Bouckenooghe,Ralf Clemens,Beatrice De Vos,Miguel O'Ryan +35 more